Human Investing LLC Has $1.13 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Human Investing LLC cut its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,942 shares of the company’s stock after selling 168 shares during the quarter. Human Investing LLC’s holdings in Johnson & Johnson were worth $1,134,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Price T Rowe Associates Inc. MD increased its position in Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after buying an additional 3,912,430 shares during the last quarter. FMR LLC increased its position in Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after buying an additional 3,229,032 shares during the last quarter. GQG Partners LLC increased its position in Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after buying an additional 2,547,378 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in Johnson & Johnson by 52.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after buying an additional 2,093,392 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in Johnson & Johnson by 37.2% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after buying an additional 1,805,632 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on JNJ shares. Barclays started coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target for the company. Sanford C. Bernstein decreased their price target on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Atlantic Securities decreased their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Finally, Bank of America decreased their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Seven equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $182.42.

Johnson & Johnson Stock Down 0.1 %

NYSE JNJ opened at $169.53 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The firm has a 50-day simple moving average of $176.15 and a 200 day simple moving average of $171.37. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The stock has a market cap of $443.23 billion, a PE ratio of 23.61, a PEG ratio of 3.28 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.60 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.67%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is 62.95%.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Peter Fasolo sold 29,275 shares of the firm’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $171.36, for a total transaction of $5,016,564.00. Following the completion of the transaction, the vice president now owns 114,676 shares in the company, valued at $19,650,879.36. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 29,275 shares of the firm’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $171.36, for a total transaction of $5,016,564.00. Following the completion of the transaction, the vice president now owns 114,676 shares in the company, valued at $19,650,879.36. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Insiders sold a total of 277,886 shares of company stock worth $48,550,549 over the last quarter. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.